MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Ophthalmology

  • Home
  • Specialties
  • Ophthalmology
  • Page 15
Veligrotug Emerges as a Promising Therapy for Thyroid Eye Disease: Insights from the THRIVE and THRIVE-2 Trials
Posted inClinical Updates Diabetes & Endocrinology news Ophthalmology Specialties

Veligrotug Emerges as a Promising Therapy for Thyroid Eye Disease: Insights from the THRIVE and THRIVE-2 Trials

Posted by By MedXY 07/31/2025
Veligrotug demonstrates robust efficacy and manageable safety in both active and chronic thyroid eye disease, positioning itself as a potential alternative to teprotumumab based on phase 3 THRIVE trial data.
Read More
GLP-1 Receptor Agonists Linked to Early Risk of Optic Nerve Damage: A Case-Control Study Analysis
Posted inClinical Updates news Ophthalmology Otorhinolaryngology Specialties

GLP-1 Receptor Agonists Linked to Early Risk of Optic Nerve Damage: A Case-Control Study Analysis

Posted by By MedXY 07/30/2025
GLP-1 receptor agonist use, especially liraglutide, is associated with a higher risk of nonarteritic anterior ischemic optic neuropathy (NAION) during the first year, particularly in patients without diabetes or obesity.
Read More

Posts pagination

Previous page 1 … 13 14 15
  • Navigating the Balance: Fostering Humanistic Practice Amidst Healthcare System Pressures
  • Targeting IL-6 Receptor Signaling Enhances Cytolytic CD4+ T Cells and Improves Outcomes After Cellular Immunotherapy
  • Global Disparities in Intensive Care Unit Resources and Organization: Insights from the ISOREA Survey
  • Quantitative Vascular Severity Scoring Enhances Insights into Retinopathy of Prematurity Across Diverse Populations
  • Swallowing Outcomes Following Early Treatment of Head and Neck Cancer-Related Lymphedema
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top